ALOSETRON HYDROCHLORIDE

Post-LOE

alosetron hydrochloride

Pfizer

ANDAORALTABLET

Approved

Sep 2019

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

ALOSETRON HYDROCHLORIDE (alosetron hydrochloride) by Pfizer is 5-ht3 receptor antagonist. First approved in 2019.

Drug data last refreshed 20h ago

Mechanism of Action

5-HT3 receptor antagonist. 5-HT3 receptors are ligand-gated cation channels that are extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels and the resulting neuronal depolarization affect the…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (1)

NCT01855711Phase 2Completed

Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)

Started Sep 2003

32 enrolled

Irritable Colon

Worked on ALOSETRON HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.